President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet's Adam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era. 

  1. Alkermes (ALKS)
  2. CytRX (CYTR)

  3. Dynavax Technologies (DVAX)

  4. Intra-Cellular Therapies (ITCI)

  5. Novan (NOVN)

  6. Portola Pharmaceuticals (PTLA)

  7. PTC Therapeutics (PTCT)

  8. Rigel Pharmaceuticals (RIGL)

  9. TG Therapeutics (TGTX)

READ THE FULL STORY HERE: These 'Gnarly 9' Biotechs Will Test the FDA's Mettle
This article was written by a staff member of TheStreet.

If you liked this article you might like

Alkermes Is Getting Ready for a Rally

Alkermes Is Getting Ready for a Rally

Alkermes: Cramer's Top Takeaways

Alkermes: Cramer's Top Takeaways

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Jobs Report Just Right for Stocks: Cramer's 'Mad Money' Recap (Friday 12/8/17)

Jobs Report Just Right for Stocks: Cramer's 'Mad Money' Recap (Friday 12/8/17)

Nucor, Alkermes, T-Mobile, Axon Enterprise: 'Mad Money' Lightning Round

Nucor, Alkermes, T-Mobile, Axon Enterprise: 'Mad Money' Lightning Round